Probatebeta
Drug

TAR-200

As of the edition of 20 October 2026, TAR-200 is a drug known only by a code name: in active development; acts on POLA1, POLA2 and POLD1 and 11 more.

Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.

The drug

Status
Active, 2030
Kind
Code name only
Registered trials
7, 0 stopped early
Disease areas
Cancer; Pregnancy and women's health; Urinary and reproductive

US protection

No US approval on record.

With no US approval on record there are no listed US patents or exclusivities.

This is the US only.

Targets

GeneProteinUniProt
POLA1DNA polymerase alpha catalytic subunitP09884
RRM1Ribonucleoside-diphosphate reductase large subunitP23921
POLD1DNA polymerase delta catalytic subunitP28340
RRM2Ribonucleoside-diphosphate reductase subunit M2P31350
POLD2DNA polymerase delta subunit 2P49005
PRIM1DNA primase small subunitP49642
PRIM2DNA primase large subunitP49643
POLE2DNA polymerase epsilon subunit 2P56282
POLEDNA polymerase epsilon catalytic subunit AQ07864
POLA2DNA polymerase alpha subunit BQ14181
POLD3DNA polymerase delta subunit 3Q15054
RRM2BRibonucleoside-diphosphate reductase subunit M2 BQ7LG56
POLD4DNA polymerase delta subunit 4Q9HCU8
POLE3DNA polymerase epsilon subunit 3Q9NRF9

Registered trials

PhaseTrialsCompletedActiveStopped early
Phase not stated1000
Phase 11100
Phase 22110
Phase 33030
All trials7

Who ran its trials

CompanyRoleYears
Johnson & JohnsonLead sponsor of trials